CClinicalTrials.gg
RecruitingNCT06835816AARRTUpdated Feb 19, 2025

Amino Acid Supplementation in Continuous Renal Replacement Therapy

An interventional study of Amino acid supplementation (Glavamin, Fresenius Kabi) in Acute Kidney Injury, sponsored by Karolinska University Hospital. Recruiting at 1 site in Sweden. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-02-19.

Sponsored by Karolinska University Hospital · Not applicable, Interventional, and Treatment

From the registry’s dates

  • Started Feb 2025; still recruiting 1 year 8 months later.
Phase
Not applicable
Study type
Interventional
Enrollment
30
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Study summary

ICU patients treated with continuous renal replacement therapy is recruited prior to start of treatment.

Blood samples are drawn and then dialysis start without amino acid supplementation. After a few hours samples are drawn from blood and dialysate. Then patients are given amino acid supplementation (33.5g/24hrs) for 20-24 hours. New samples are drawn and amino acid supplementation is increased to 67g/24hrs and new samples are drawn after additional 24 hours. Then CRRT will continue with the full amino acid supplementation (standars of care).

02

Conditions studied

  • Acute Kidney Injury

Browse trials for

03

In context

Acute Kidney Injury

1,595 studies on the registry are indexed under Acute Kidney Injury; 371 are open to participants now.

This study's planned enrollment of 30 is below the median of 100 across 763 interventional studies indexed under Acute Kidney Injury.

Browse Acute Kidney Injury studies →

Lead sponsor

Karolinska University Hospital is the lead sponsor of 275 studies on the registry; 54 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

  • Dialysis where amino acid supplementation is planned by treating physician

Exclusion criteria

Exclusion Criteria:

  • Liver failure
  • Muscle disease
  • Neurodegenerative disease
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
30 participants (estimated)

Study arms

  • Experimental
    All patients

    All patients will start CRRT treatment without amino acid supplementation After a few hours samples are drawn from blood and dialysate Patients then receive low dose of supplementation for 24 hours (33.5g, 250 ml Glavamin, Fresenius Kabi) and new samples are drawn After that patients receive full supplementation (67g, 500 ml Glavamin, Fresenius Kabi) for the rest the of CRRT treatment. After 24 hours of this treatment new samples are drawn.

    Dietary Supplement: Amino acid supplementation (Glavamin, Fresenius Kabi)

Interventions

  • Dietary supplementAmino acid supplementation (Glavamin, Fresenius Kabi)

    Mixture of amino acids (67 g / 500 ml) given intravenously

06

What researchers measure

Primary outcomes

  1. Balance of amino acids

    Total balance of amino acid losses and supplementation given

    Time frame: After 3 days of dialysis

Secondary outcomes

  1. Amino acid concentration in plasma

    Concentration of various amino acids in plasma without and with supplementation

    Time frame: After 3 days of dialysis

  2. Concentration of vitamins and trace elements

    Analysis of various trace elements and vitamins

    Time frame: After 3 days of dialysis

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: Undecided — Data will be availible per request

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Feb 19, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06835816
Lead sponsor
Karolinska University Hospital
Responsible party
Jonathan Grip (MD, PhD, Karolinska University Hospital) — Principal investigator
First posted
Feb 19, 2025
Start date
Feb 3, 2025
Primary completion
Dec 31, 2026 (estimated)
Completion
Dec 31, 2028 (estimated)
Last update
Feb 19, 2025

Study contacts

Jonathan Grip, MD, PhD
Contact
jonathan.grip@regionstockholm.se
+46736230906
Jonathan Grip, MD, PhD
principal investigator · Karolinska University Hospital

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion